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We performed a postmarketing surveillance study to determine the efficacy and safety 
of the oral quinolone antibacterial agent, garenoxacin (Geninax® Tablets 200 mg), 
against bacterial pneumonia. 
Between October 2009 and March 2011, patients with community-acquired pneumonia 
visited 174 facilities in Japan; we collected survey forms from 739 patients of these 
patients who were suspected with bacterial pneumonia on the basis of factors, e.g., the 
presence of purulent sputum or suspected presence of bacterial pathogens in clinical 
specimens. We examined the safety in 730 patients and the efficacy in 535 patients. 
The efficacy rate of garenoxacin for bacterial pneumonia was 92.8% (479/516 
patients). The eradication rates for Streptococcus pneumoniae and Haemophilus 
influenzae, the major pathogens of bacterial pneumonia, were 98.5% (65/66 strains) and 
100% (65/65 strains), respectively. 
The incidence of adverse drug reactions (including abnormal laboratory tests) was 
7.9% (58/730 patients). Among the main adverse drug reactions, abnormal laboratory 
tests were observed in 2.1% patients (15/730), hepatobiliary disorders were observed in 
1.8% patients (13/730), and skin and subcutaneous tissue disorders were observed in 
1.6% patients (12/730). 
In conclusion, garenoxacin showed an efficacy rate of greater than 90% for bacterial 
pneumonia and is considered to be useful in daily practice. 
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Garenoxacin (GRNX) is an oral quinolone antibiotic manufactured by Toyama 
Chemical Co., Ltd. (Tokyo, Japan); the company obtained the approval for 
manufacturing and marketing this medication in July 2007 under the product name 
Geninax® Tablets 200 mg. GRNX has a novel and unique chemical structure with lack of 
fluorine atom at the 6-position of the quinolone skeleton, which is normally considered 
essential to the antibacterial activity of conventional fluoroquinolones. GRNX shows 
excellent antibacterial activity against major bacterial pathogens in respiratory and 
otorhinolaryngological infections by inhibiting type II topoisomerases (DNA gyrase and 
topoisomerase IV), which are involved in bacterial DNA replication. In addition, GRNX 
shows strong antibacterial activity against penicillin-resistant Streptococcus pneumoniae, 
the increasing prevalence of which in the recent years has become a cause of concern [1, 
2]. Further, because this drug shows a large AUC [3] and good tissue penetration [4, 5] 
after administration of a single dose of 400 mg/day, plasma concentrations in excess of 
the mutant prevention concentration for S. pneumoniae and Staphylococcus aureus were 
obtained for more than 24 h. Thus, GRNX is expected to prevent the emergence of 
drug-resistant strains [6]. 
In the clinical development study of GRNX, however, evaluable patients were limited 
to those who met strict inclusion and exclusion criteria to accurately assess the efficacy 
and safety of GRNX. Such development study might not necessarily reflect the actual 
patient population. Thus, we conducted a study in patients treated with GRNX in daily 
clinical practice basis. 
In this study, we performed a specified postmarketing surveillance study to confirm 
the efficacy and safety of GRNX against bacterial pneumonia (including 
community-acquired pneumonia and nursing and healthcare-associated pneumonia 
[NHCAP], not including hospital-associated pneumonia) in daily clinical practice. We 
collected data regarding efficacy, safety, and causative bacterial pathogens in patients 
with bacterial pneumonia with various backgrounds. 
 
 
(2) Patients and methods 
 
(2)-1 Target patients 
The study was conducted in patients who were treated at 174 medical institutions 
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across Japan between October 2009 and March 2011 and who met the following 
inclusion and exclusion criteria (Table 1). 
The inclusion criteria were as follows: 
1. Patients who were 15 years or older 
2. Patients who had infiltrative shadows that thought to have appeared acutely and 
newly on chest radiographic images and not exceeding 2/3 of one lung 
3. Patients who had purulent sputum or in whom a bacterial pathogen was presumed 
to be present in clinical specimens (e.g., the sputum) or who had a positive result 
in urinary antigen test 
4. Patients who had respiratory symptoms (e.g., cough, chest pain, or dyspnea) 
5. Patients who could ingest orally 
6. Patients who had no concomitant atypical pneumonia as confirmed by rapid 
diagnosis (ImmunoCard® Mycoplasma, Meridian, USA) when GRNX therapy was 
initiated 
7. Patients who did not require a combination of other antibiotics or steroids when 
GRNX therapy was initiated (however, patients undergoing long-term treatment 
with a low-dose macrolide antibiotic at a fixed dose or patients receiving a drug 
with a prednisolone conversion of ≤30 mg/day at a fixed dose continued these 
regimens) 
8. Patients who took no other antibiotics within 7 days before initiation of GRNX 
therapy (however, patients in whom other antibiotics were considered to be 
ineffective and infection was detected were allowed) 
The exclusion criteria were as follows: 
1. Patients who had a history of hypersensitivity to GRNX or other quinolones 
2. Patients who were pregnant or possibly pregnant or were lactating 
3. Patients who previously enrolled in the study 
4. Patients in whom drug efficacy of GRNX was difficult to assess 




This study was performed as a prospective study using a central registration system. 
The patients were registered on the registration center until the day after the beginning of 
GRNX. Informed consent and ethics committee approval were obtained as required for 
postmarketing surveillance. The survey items were as follows: patient characteristics 
(sex, age, inpatient/outpatient, weight, infectious disease diagnosis, severity of 
pneumonia [A-DROP scoring system], underlying diseases [diseases related to 
4 
pneumonia], complications [diseases not related to pneumonia], hepatic function disorder 
before GRNX therapy, renal impairment before GRNX therapy, and history of adverse 
drug reactions or allergies); antibiotics taken immediately before (within 1 week) 
initiation of GRNX therapy; administration status of GRNX (dose, number of doses, and 
administration period); concomitant drugs; combination therapies; clinical symptoms and 
signs; laboratory tests; bacteriological examinations; clinical efficacy; and adverse 
events. Rapid diagnosis and serological tests were performed as required. 
GRNX was administered under the approved regimen, and the administration period 
was not limited. Concomitant drugs and combination therapies were not limited. 
The observation period was until the termination of GRNX therapy, and adverse events 
were monitored until 4 days after GRNX therapy was terminated. 
 
(2)-3 Efficacy evaluation 
The clinical efficacy and bacteriological efficacy (prevalence of bacteria) were 
examined. Clinical efficacy was assessed at the termination of GRNX therapy and was 
classified as “effective,” “ineffective,” or “evaluation not possible” according to clinical 
efficacy criteria [7] (Table 2). In patients receiving GRNX for 10 days or more, an 
additional assessment was made on the 10th day after initiation of GRNX. Bacteriological 
efficacy (prevalence of bacteria) was classified as bacterial “eradication” or 
“persistence” according to bacteriological efficacy criteria [7] on the basis the 
bacteriological examination results before and after GRNX therapy. 
Safety was evaluated on the basis of the occurrence of adverse drug reactions. Adverse 
drug reactions were any events which a causal relationship with GRNX could not be 
denied during the observation period, such as medically unfavourable and unintended 
signs and symptoms (e.g., abnormal changes in laboratory tests and clinical symptoms 
and signs). Exacerbation of the pneumonia because of insufficient response to GRNX 
was not included. 
 
(2)-4 Assessment of judgment/totalization results 
An evaluation committee was formed with 5 members (one principal investigator, 
three coordinating investigators, and a representative physician) to discuss whether to 
include the problem cases, the handling of data in cases that deviated from the protocol, 
the handling of bacterial pathogens, and causal relationships between adverse events and 
GRNX therapy. 
The term “bacterial pathogens” referred to bacteria that were detected at a score of 
≥3+ (the level of ≥105 colony-forming units/ml) derived from sputum. S. pneumoniae 
and Haemophilus influenzae detected at a clear level were classified as bacterial 
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pathogens. In addition, positive S. pneumoniae urinary antigen test results and positive 
Chlamydophila pneumoniae and Mycoplasma pneumoniae serological test results were 
also obtained to detect bacterial pathogens. 
Adverse drug reactions were analyzed using the Medical Dictionary for Regulatory 
Activities, Japanese version (MedDRA/J, ver. 15.0). 
 
(2)-5 Analysis sets 
Efficacy was evaluated in the patients in the efficacy analysis set, which included 
patients from whom survey forms were collected and who met the inclusion and 
exclusion criteria and who received GRNX under the approved regimen. The safety was 
evaluated in the patients in the safety analysis set from whom survey forms were 
collected and who received GRNX at least one time. 
 
(2)-6 Statistical analysis 
Statistical analysis was performed using χ2 test for comparison, and when the 





(3)-1 Analysis sets and patient characteristics 
The analysis sets are shown in Figure 1. 
Patient characteristics of efficacy and safety analysis sets are shown in Table 3. 
Among the safety analysis set, 59.0% of patients were male with an average age of 
61.6 years and 51.8% (of the total set) were elderly (≥65 years). Moreover, 90.5% were 
outpatients, 62.2% experienced mild pneumonia according to the A-DROP scoring 
system, and 36.7% experienced moderate pneumonia. Underlying diseases (diseases 
related to pneumonia) and complications (diseases not related to pneumonia) were 
observed in 47.1% and 51.2% of the patients, respectively, both accounting for 
approximately half of the patients. The maximum daily dose of GRNX was 400 mg, 
which was administered to a majority of the patients (98.2%). In 13 patients, the dose 
was adjusted to 200 mg per day by attending physicians because of low weight (<40 kg), 
advanced renal impairment, advanced age (≥75 years), or the presence of adverse events. 
The average administration period was 8.7 ± 3.6 days, with the greatest number of 
patients at 3 to 7 days (48.6%), followed by 8 to 14 days (44.2%). Patient characteristics 
in the efficacy analysis set were almost same as those in the safety analysis set. 
In patients from whom survey forms were collected, bacterial culture before GRNX 
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therapy was performed in the specimens collected from 635 patients. Rapid diagnosis 
and serological test of bacterial pathogens were performed in 434 patients; S. 
pneumoniae urinary antigen test was performed in 399 patients, C. pneumoniae 
serological test in 88 patients, and M. pneumoniae serological test in 191 patients, 
respectively. We detected 289 strains of bacterial pathogens from 271 patients. The main 
bacterial pathogens detected were S. pneumoniae at 45.3% (131/289 strains), followed by 
H. influenzae at 35.6% (103/289 strains), Moraxella (Branhamella) catarrhalis at 5.9% 
(17/289 strains), M. pneumoniae at 4.2% (12/289 strains), and C. pneumoniae at 3.1% 
(9/289 strains) (data not shown). 
 
(3)-2 Clinical efficacy 
The clinical efficacy findings are shown in Table 4. 
The efficacy rate of GRNX at the time of the termination, excluding patients with an 
indeterminate result, was 92.8% (479/516 patients). The efficacy rates according to age 
were >90% in both the non-elderly and elderly groups. The efficacy rate according to the 
presence or absence of underlying diseases or complications was 88.9% (209/235 
patients) in patients with underlying diseases, 89.3% (243/272 patients) in patients with 
complications, 96.0% (267/278 patients) in patients without underlying diseases, and 
96.7% (236/244 patients) in patients without complications. In addition, the efficacy rate 
was 97.1% (135/139 patients) in 139 of 143 patients who were evaluated for clinical 
efficacy on the 10th day after initiation of GRNX administration (Four inevaluable 
patients were excluded). 
The clinical efficacy for elderly and non-elderly patients is shown in Table 5. 
The efficacy rate was slightly lower in elderly patients with moderate pneumonia. The 
efficacy rate in the elderly with underlying diseases was lower by approximately 6–10% 
(86.9% [139/160 patients]) than that in the elderly and non-elderly patients with no 
underlying diseases as well as non-elderly patients with underlying diseases. The 
efficacy rate in elderly and non-elderly patients with complications was lower by 
approximately 3–10% than that in patients without complications (89.4% [169/189 
patients] in elderly and 89.2% [74/83 patients] in non-elderly with complications). 
The efficacy rate in patients receiving antibiotic treatment prior to GRNX therapy 
(within 7 days before beginning administration) was lower by approximately 3% (89.8%, 
53/59 patients) than that in patients not without antibiotic treatment (93.1%, 418/449 
patients) (Table 4). The antibiotic treatment before GRNX therapy primarily consisted of 
oral medications, e.g., clarithromycin (CAM), cefcapene pivoxil (CFPN-PI), and 
azithromycin (AZM). 
The breakdown of 37 patients for whom treatment was determined to be ineffective at 
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the time of the termination of GRNX therapy according to age and underlying diseases is 
shown in Table 6. 
Efficacy was evaluated in 252 non-elderly patients and 283 elderly patients after the 
termination of GRNX therapy. The treatment was found to be ineffective in 4.4% (11/252 
patients) of the non-elderly and 9.2% (26/283 patients) of the elderly patients. Among the 
elderly patients with underlying diseases, many had chronic respiratory diseases, and this 
differed from the underlying diseases of the non-elderly. The elderly and the non-elderly 
patients had diabetes mellitus, hypertension, rheumatoid arthritis, and other 
complications, but no differences were observed according to age. 
In the efficacy analysis set, 7 patients received concomitant administration of other 
antibiotics after the initiation of GRNX therapy, and the treatment was effective in 2 out 
of 6 patients (Table 4). GRNX was determined as ineffective in 4 patients for the 
following reasons; pyrexia at the termination of GRNX administration, insufficient 
efficacy at the time of admission for atrial fibrillation, progression to pyothorax, 
diagnosed with mycobacteriosis after initiation of GRNX administration. In addition, 9 
patients were suspected with bacterial pneumonia before GRNX therapy, and the 
bacterial pathogens in these patients were identified as the atypical pathogens C. 
pneumoniae and M. pneumoniae after the initiation of GRNX therapy; the efficacy rate in 
these patients for infection of only atypical pathogens was 4/6 patients, and for mixed 
infection of bacterial and atypical pathogens was 3/3 patients (Table 7). GRNX was 
determined as ineffective in 2 patients for the following reasons; insufficient efficacy and 
cryptogenic organizing pneumonia. 
The overall rate of eradication of bacteria was 98.6% (143/145 strains); that of S. 
pneumoniae was 98.5% (65/66 strains) and H. influenzae was 100% (65/65 strains). 
Species that could not be collected in sufficient quantities at the time of GRNX 
development were Streptococcus species and Enterobacter cloacae, the rates of 
eradication were 2/2 strains and 1/1 strains (data not shown). 
 
(3)-3 Adverse drug reactions 
Overall, 71 adverse drug reactions related with GRNX were observed in 58 patients, 
and the incidence of adverse drug reaction was 7.9% (58/730 patients) (Table 8). 
Hepatobiliary disorders and skin and subcutaneous tissue disorders were more frequently 
reported in non-elderly than in elderly patients. However, no remarkable difference in the 
incidence of adverse drug reactions overall was noted between non-elderly and elderly 
patients. Four severe adverse drug reactions were reported in 3 patients; one patient had 
eosinophilic pneumonia, one patient had atrial fibrillation, and one patient had decreased 
blood pressure and dyspnea. No patients died of these severe adverse drug reactions. 
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GRNX therapy was discontinued in the two patients who experienced eosinophilic 
pneumonia and who had decreased blood pressure with dyspnea. The GRNX therapy was 




The clinical efficacy (efficacy rate) of GRNX in patients with suspected bacterial 
pneumonia, not including hospital-acquired pneumonia, was 92.8% (479/516 patients). 
The efficacy of GRNX was good (89.8% [53/59 patients]) even in patients who had 
received antimicrobial therapies, e.g., CAM, CFPN-PI, and AZM within 1 week before 
the initiation of GRNX administration and were considered clinical failures. GRNX 
showed high efficacy (>90%) in non-elderly and elderly patients, but the efficacy rate 
was significantly lower in the elderly patients (p = 0.0264). Of the elderly patients, only 
30% had mild pneumonia and >60% had moderate pneumonia, based on the severity 
scoring system A-DROP, while among the non-elderly patients, 90% had mild 
pneumonia. Patients with underlying diseases accounted for approximately 60% of 
elderly patients; in contrast, only 30% of non-elderly patients had underlying diseases. 
We hypothesize that the difference in the efficacy rate between elderly and non-elderly 
patients was because of differences in the severity of pneumonia and in the prevalence of 
underlying diseases. The elderly patients in whom GRNX therapy failed often had 
chronic respiratory diseases (Table 6), and these patients might have developed 
pneumonia due to acute exacerbation of chronic respiratory diseases. Bacterial pathogens 
were not detected in most of these patients, and opportunistic pathogens (e.g., 
Pseudomonas aeruginosa, Escherichia coli, and Nocardia species) were detected in the 
amount of + or 2+ score. 
Furthermore, the efficacy rate of GRNX in the elderly patients might have been lower 
than that in the non-elderly patients because the elderly patient group included patients 
with intractable conditions (e.g., aspiration pneumonia). In Japan, the clinical practice 
guidelines for NHCAP published in 2011 indicate that NHCAP develops frequently in 
elderly patients with aspiration pneumonia [8]; however, we were unable to consider this 
point since this study was conducted before the announcement of the guidelines. In the 
clinical practice guidelines for NHCAP, GRNX is recommended as one of the empirical 
treatment drugs for patients who do not require hospitalization [8]; in this study, the 
efficacy rate of GRNX was high (>85%) in the populations which could include patients 
with intractable NHCAP, i.e., elderly patients with moderate pneumonia or with 
underlying diseases related to pneumonia. 
Our results were consistent with those of a GRNX efficacy analysis in >6,000 patients 
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reported by Hori et al. [9]; they reported that the efficacy rate was >90% and that age, 
underlying diseases, and complications reduced the effectiveness of GRNX therapy. 
In this study, we confirmed the efficacy of GRNX for the administration period in 
clinical practice, and there was no statistical difference in the efficacy rates between the 
administration periods of 6–7 days, 8–10 days, and 11–14 days. In patients with mild and 
moderate pneumonia, the efficacy rates by the administration period of 6–7 days, 8–10 
days, and 11–14 days was approximately 90%. As shown in Table 5, >90% of the patients 
with moderate pneumonia were elderly. Considering the fact that the efficacy rate in 
these patients was equivalent to that in the non-elderly patients with pneumonia of the 
same severity, GRNX is expected to have a therapeutic effect for an administration 
period of 6–7 days, regardless of whether the patient is elderly or non-elderly. An 
overseas postmarketing surveillance study of moxifloxacin (MFLX) showed that the 
clinical efficacy of MFLX was 96.6% for an administration period of 5–10 days in 
patients with bacterial pneumonia [10], and we consider that we obtained similar results 
in our study. Furthermore, 36 patients received long-term GRNX therapy (≥15 days) in 
the efficacy analysis set. Of these patients, 19 exhibited an improved outcome on the 10th 
day after the initiation of GRNX therapy, but the therapy was continued in these patients. 
In future studies, it is important to clarify the duration of GRNX outpatient treatment. 
The major bacterial pathogens were S. pneumoniae at 45.3% (including 10.7% with 
positive results only in the urinary antigen test) and H. influenzae at 35.6%. These 
findings were similar to those reported by Saito et al. [11] and Miyashita et al. [12]. The 
eradication rates of S. pneumoniae and H. influenzae were >95%, and the overall 
eradication rate was 98.6%. In the efficacy analysis set, the indicated bacteria were not 
detected as bacterial pathogens in 345 patients, but GRNX showed high efficacy in these 
patients at the time of GRNX therapy termination (90.6% [288/318 patients]). 
The incidence of adverse drug reactions was 7.9% (58/730 patients). There were no 
serious issues regarding safety, because no adverse drug reaction specific to GRNX was 
observed. 
In conclusion, we confirmed the usefulness of GRNX for mild to moderate bacterial 
pneumonia in daily clinical practice. Further studies would be required to clarify the 
appropriate timing of GRNX termination. 
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Table 1. List of the investigating medical institutions 
 
Yamamoto Kumiai Hospital   Eiju General Hospital   Tokyo Medical University Kasumigaura Hospital     
JR Tokyo General Hospital     St. Luke’s International Hospital     Nakano General Hospital   
NTT WEST Kyushu Hospital     Jyuzen General Hospital     The Jikei University Hospital    
Saitama Red Cross Hospital     Ohta Nishinouchi Hospital    Tokyo Women’s Medical University Medical Center East  
Aichi Medical University Hospital    Nagano Municipal Hospital    Tokyo Metropolitan Hiroo Hospital    
Toyota Kosei Hospital  Tenri Hospital     Tokyo Metropolitan Fuchu Hospital    
Kyorin University School of Medicine    Ebara Hospital    Higashiosaka City General Hospital    
Isesaki Municipal Hospital     Jusendo General Hospital    Toho University Sakura Medical Center   
Izumikawa Hospital    Nissan Tamagawa Hospital     Toho University Ohashi Medical Center   
Aino Hospital    Southern Tohoku General Hospital   Toho University Omori Medical Center   
Mito Chuo Hospital    Saitama Medical Center     Fujita Health University Hospital    
St. Mary’s Hospital  Mie Prefectural General Medical Center    Bell Land General Hospital   
Nippon Steel Yawata Memorial Hospital    University of Occupational and Environmental Health   
National Hospital Organization Matsumoto Medical Center 
 Chushin Matsumoto Hospital 
Hanzomon Hospital    Itami City Hospital      National Hospital Organization Ibarakihigashi National Hospital 
Niigata Rinko Hospital   Kofu City Hospital      National Hospital Organization Ureshino Medical Center  
Nishifukuoka Hospital     Yokkaichi Municipal Hospital     National Hospital Organization Kanazawa Medical Center  
Kusatsu General Hospital    Suita Municipal Hospital     National Hospital Organization Kyushu Medical Center  
Fukuoka Seisyukai Hospital    Ikeda City Hospital      National Hospital Organization Kumamoto Medical Center  
Tenshi Hospital    Toyonaka Municipal Hospital     National Hospital Organization Kumamoto Saishunso National Hospital 
Sasaki Naika    Shiga Medical Center for Adults     National Hospital Organization Kochi National Hospital  
Tsuchiura Kyodo General Hospital  Jichi Medical University Saitama Medical Center   National Hospital Organization National Disaster Medical Center 
Ibaraki Seinan Medical Center Hospital    Jichi Medical University Hospital     National Hospital Organization Sanyo National Hospital  
Yokosuka City Hospital     Saiseikai Suita Hospital   National Hospital Organization Shiga National Hospital  
Okazaki City Hospital     Saiseikai Nagasaki Hospital   National Hospital Organization Mito Medical Center  
Shimonoseki City Central Hospital    Tokyo Saiseikai Central Hospital   National Hospital Organization Nishibeppu National Hospital  
Kitasato University Kitasato Institute Hospital   Saiseikai Utsunomiya Hospital  National Hospital Organization Omuta National Hospital  
Kansai Electric Power Hospital     Kyoto-Katsura Hospital    National Hospital Organization Nagasaki Medical Center  
Nishimino Kosei Hospital  Shinrakuen Hospital    National Hospital Organization Tenryu Hospital   
Miyazaki Prefectural Nobeoka Hospital    Seirei Yokohama Hospital    National Hospital Organization Tokyo Medical Center  
Japanese Red Cross Kyoto Daini Hospital   Seirei Mikatahara General Hospital   National Hospital Organization Higashihiroshima Medical Center 
Kanazawa Medical University Hospital    Seirei Hamamatsu General Hospital   National Hospital Organization Minami Kyushu National Hospital 
Isahaya Health Insurance General Hospital    The Fraternity Memorial Hospital    National Hospital Organization Himeji Medical Center  
Kinki Central Hospital 
 of Mutual Aid Association of Public School Teachers 
  Utsunomiya Social Insurance Hospital   National Hospital Organization Hamada Medical Center  
Kyushu Central Hospital 
 of Mutual Aid Association of Public School Teachers 
  Tohoku Kosei Nenkin Hospital   National Hospital Organization Fukuoka Higashi Medical Center 
Chugoku Central Hospital 
 of Mutual Aid Association of Public School Teachers 
  Nagoya Ekisaikai Hospital    Kyushu Rosai Hospital, Japan Labour Health and Welfare Organization 
12 
Kanzaki Municipal General Hospital    Akashi Medical Center    Chiba Rosai Hospital, Japan Labour Health and Welfare Organization 
Yokohama City University Medical Center  Juntendo University Urayasu Hospital    Tokyo Rosai Hospital, Japan Labour Health and Welfare Organization 
Yokohama City University Hospital   Juntendo University Hospital     Nippon Medical School Chiba Hokusoh Hospital   
Fukushima Medical University Hospital    Showa University Fujigaoka Hospital     Japanese Red Cross Nagasaki Genbaku Hospital   
Naga Hospital     Sado General Hospital    Japanese Red Cross Nagasaki Genbaku Isahaya Hospital  
Onomichi General Hospital   Niigata Prefectural Central Hospital     Ohtawara Red Cross Hospital   
Hiroshima General Hospital   Niigata City General Hospital     Nihon University Itabashi Hospital    
Hiroshima City Asa Hospital    Isehara Kyodo Hospital   Iida Municipal Hospital     
Toranomon Hospital   St. Marianna University Yokohama City Seibu Hospital   Iwata City Hospital     
Sasebo Kyosai Hospital   St. Marianna University Hospital     Toyama Prefectural Central Hospital    
Tokyo Kyosai Hospital   Nishinomiya Municipal Central Hospital    Toyama University Hospital    
Hamanomachi Hospital   Shizuoka City Shimizu Hospital     Fukui Prefectural Hospital    
Asahikawa Medical University Hospital    Ishikawa Prefectural Central Hospital     Fukui Social Insurance Hospital    
Kanazawa University Hospital    Kawasaki Municipal Ida Hospital     Fukuoka University Hospital    
Kyushu University Hospital    Funabashi Municipal Medical Center     Takarazuka City Hospital    
Kumamoto University Hospital   Osaka Saiseikai Nakatsu Hospital     Toyohashi Municipal Hospital    
Gunma University Hospital   Japanese Red Cross Otsu Hospital     Hokkaido Social Insurance Hospital    
Kochi Medical School Hospital   Oita Prefectural Hospital     Kitasato University Hospital    
Mie University Hospital   Oita Red Cross Hospital     Dokkyo Medical University Koshigaya Hospital   
Shiga University of Medical Science Hospital   Osaka Prefectural Medical Center for Respiratory and Allergic Diseases        
Niigata University Medical & Dental Hospital   Nagasaki Municipal Medical Center           
Nagasaki University Hospital  Teikyo University Chiba Medical Center          
The University of Tokyo Hospital   Teikyo University School of medicine University Hospital, Mizonokuchi        
National Center for Geriatrics and Gerontology   Tonosho Central Hospital           
Sasaki Institute Kyoundo Hospital    Tokai University Tokyo Hospital           
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Table 2. Clinical efficacy criteria 
 
Evaluation  Evaluation criteria 
Effective 
 
Of the conditions (1) to (3) below, if the following items are met; condition (1) fulfills its condition; 
either condition (2) or (3) satisfies these conditions; and remaining condition does not lead to 
exacerbation, it is classified as “effective.” 
       
  (1) Improvement or disappearance of the symptoms and signs of pneumonia  
   A determination of maximum body temperature, cough, sputum (amount, properties), dyspnea, 
chest pain, or chest rales. 
    (a) Improvement in the symptoms and signs of 1 item or more.  
    (b) In cases of fever at the initiation of administration (or registered), the fever must improve. 
     If the fever declines after the initiation of administration (or registered), even if body 
temperature is 37.0°C or more, it will be treated as an improvement. 
  (2) If all abnormalities in chest X-ray shadows improve or disappear   
   Determined on the basis of the density and spread of the chest X-ray shadow.  
  (3) Improvement or disappearance of inflammation    
   No exacerbated items and if the following 2 items are met, “Improvements to 9000/μl or less of 
the peripheral blood white blood cell count” or “Decline from the highest value of CRP.” 
The change within the range of normal level is not considered. 
Ineffective  If the above criteria are not “effective,” the case is determined to be “ineffective.” 
Evaluation not possible  If it is not possible to determine either “effective” or “ineffective,” it is classified as “evaluation not possible.” 
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Table 3. Patient characteristics 
 
Item Category 












Number of patients for analysis  730  535 
Sex 
Male  431 (  59.0 )  321 (  60.0 ) 
Female  299 (  41.0 )  214 (  40.0 ) 
Age 
Non-elderly 
(<65 years of age) 
 352 (  48.2 )  252 (  47.1 ) 
Elderly 
(≥65 years of age) 
 378 (  51.8 )  283 (  52.9 ) 
Mean  61.6  62.1 
Inpatient/Outpatient 
Inpatient   69 (   9.5 )   47 (   8.8 ) 
Outpatient  661 (  90.5 )  488 (  91.2 ) 
Weight (kg) Mean  55.05  55.22 
Severity of pneumonia 
(A-DROP scoring system) 
Mild   454 (  62.2 )   327 (  61.1 ) 
Moderate  268 (  36.7 )  202 (  37.8 ) 
Severe  3 (   0.4 )  2 (   0.4 ) 
Extremely severe  5 (   0.7 )  4 (   0.7 ) 
Underlying diseases 
No  382 (  52.3 )  286 (  53.5 ) 
Yes  344 (  47.1 )  246 (  46.0 ) 
Unknown  4 (   0.5 )  3 (   0.6 ) 
 Bronchial asthma   102 (  14.0 )  71 (  13.3 ) 
 COPD   91 (  12.5 )  65 (  12.1 ) 
 Bronchiectasis   53 (   7.3 )  44 (   8.2 ) 
 Emphysema   50 (   6.8 )  34 (   6.4 ) 
 Interstitial lung disease   21 (   2.9 )  14 (   2.6 ) 
 Other   104 (  14.2 )  74 (  13.8 ) 
Complications   374 (  51.2 )  284 (  53.1 ) 
 Hypertension   149 (  20.4 )  119 (  22.2 ) 
 Diabetes mellitus   64 (   8.8 )  51 (   9.5 ) 
 Hyperlipidemia   56 (   7.7 )  44 (   8.2 ) 
 Insomnia   39 (   5.3 )  26 (   4.9 ) 
 Constipation   32 (   4.4 )  22 (   4.1 ) 
 Other   290 (  39.7 )  218 (  40.7 ) 
Antibiotic taken immediately 
before the initiation of 
GRNX 
Yes  95 (  13.0 )  62 (  11.6 ) 
Unknown  12 (   1.6 )  8 (   1.5 ) 
Maximum daily dosage (mg) 
200  13 (   1.8 )  7 (   1.3 ) 
400  717 (  98.2 )  528 (  98.7 ) 
Mean  396.4  397.4 
Administration period (days) 
<3  6 (   0.8 )  2 (   0.4 ) 
3–7  355 (  48.6 )  262 (  49.0 ) 
8–14  323 (  44.2 )  242 (  45.2 ) 
15–21  41 (   5.6 )  26 (   4.9 ) 
22≤  5 (   0.7 )  3 (   0.6 ) 
Mean  8.7  8.7 
S.D.  3.6  3.4 
Concomitant drug 
No  69 (   9.5 )  50 (   9.3 ) 
Yes  661 (  90.5 )  485 (  90.7 ) 
 
Antibiotic 
No  704 (  96.4 )  528 (  98.7 ) 
  Yes  26 (   3.6 )  7 (   1.3 ) 
COPD: chronic obstructive pulmonary disease       
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Table 4. Clinical efficacy according to patient characteristics 
 
Item Category 











Number of patients for efficacy analysis   535 479 37 19 92.8  
Sex 
Male  321 280 30 11 90.3  
Female  214 199 7 8 96.6  
Age 
Non-elderly 
(<65 years of age) 
  252 233 11 8 95.5  
Elderly 
(≥65 years of age) 
  283 246 26 11 90.4  
Inpatient/Outpatient 
Inpatient  47 40 4 3 90.9  
Outpatient  488 439 33 16 93.0  
Severity of pneumonia                            
(A-DROP scoring system) 
Mild   327 298 17 12 94.6  
Moderate  202 176 20 6 89.8  
Severe  2 2 0 0 2/2 
Extremely severe  4 3 0 1 3/3 
Underlying disease 
No   286 267 11 8 96.0  
Yes  246 209 26 11 88.9  
Unknown  3 3 0 0 3/3 
Complication 
No   251 236 8 7 96.7  
Yes  284 243 29 12 89.3  
Antibiotic taken immediately 
before the initiation of GRNX 
No   465 418 31 16 93.1  
Yes  62a 53 6 3 89.8  
Unknown  8 8 0 0 8/8 
Concomitant drug 
No   50 43 5 2 89.6  
Yes  485 436 32 17 93.2  
 Antibiotic 
No   528 477 33 18 93.5  
Yes  7 2 4 1 2/6 
Administration period (days) 
2–3   10 2 5 3 2/7 
4–5  38 28 6 4 82.4  
6–7  216 199 13 4 93.9  
8–10  143 135 5 3 96.4  
11–14  99 92 3 4 96.8  
15–21  26 21 4 1 84.0  
22≤   3 2 1 0 2/3 
Efficacy rate = (Number of patients considered as “Effective”) / (Number of patients considered as “Effective” and 
“Ineffective”) 
aclarithromycin, 18 patients (including 1 patient: concomitant lincomycin injection); cefcapene pivoxil, 8 patients; 
azithromycin, 7 patients; levofloxacin, 4 patients; others, 25 patients
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Table 5. Clinical efficacy according to elderly/non-elderly classification (at termination of garenoxacin therapy) 
 
Item                                    Category






















Number of patients for efficacy analysis   252 233 11 8 95.5*    283 246 26 11 90.4*  
Sex 
Male   140 129 8 3 94.2    181 151 22 8 87.3  
Female  112 104 3 5 97.2   102 95 4 3 96.0  
Inpatient/Outpatient 
Inpatient   18 17 0 1 100    29 23 4 2 85.2  
Outpatient  234 216 11 7 95.2   254 223 22 9 91.0  
Severity of 
pneumonia                                   
(A-DROP scoring 
system) 
Mild   235 217 10 8 95.6    92 81 7 4 92.0  
Moderate  14 13 1 0 92.9   188 163 19 6 89.6  
Severe  0 0 0 0 -  2 2 0 0 2/2 
Extremely severe  3 3 0 0 3/3  1 0 0 1 - 
Underlying disease 
No   174 162 6 6 96.4    112 105 5 2 95.5  
Yes  77 70 5 2 93.3   169 139 21 9 86.9  
Unknown  1 1 0 0 1/1  2 2 0 0 2/2 
Complication 
No   165 159 2 4 98.8    86 77 6 3 92.8  
Yes  87 74 9 4 89.2   197 169 20 8 89.4  
Administration 
period (days) 
2–3   2 1 1 0 1/2   8 1 4 3 1/5 
4–5  19 15 2 2 88.2   19 13 4 2 76.5  
6–7  107 104 3 0 97.2   109 95 10 4 90.5  
8–10  66 62 2 2 96.9   77 73 3 1 96.1  
11–14  46 41 1 4 97.6   53 51 2 0 96.2  
15–21  10 9 1 0 90.0   16 12 3 1 80.0  
22≤   2 1 1 0 1/2   1 1 0 0 1/1 
Efficacy rate = (Number of patients considered as “Effective”) / (Number of patients considered as “Effective” and “Ineffective”) 
* p = 0.0264
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Table 6. List of ineffective cases with patients’ underlying diseases according to age 
 
Item 






(<65 years of age) 
Elderly 
(≥65 years of age) 
Number of cases considered as 
“Ineffective” 
 37 11 26 
Underlying disease 
No  11 6 5 
Yes  26 5 21 
 COPD   6 0 6 
 Bronchial asthma   6 1 5 
 Emphysema   6 0 6 
 Bronchiectasis   4 0 4 
 Chronic bronchitis   2 1 1 
 Upper respiratory infection   1 0 1 
 Diffuse panbronchiolitis   1 0 1 
 Malignant neoplasm of lung   3 1 2 
 Non-small cell lung carcinoma   1 1 0 
 Bronchopulmonary aspergillosis   1 0 1 
 Pulmonary tuberculosis   2 1 1 
 Interstitial lung disease   1 0 1 
COPD: chronic obstructive pulmonary disease
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Table 7. Clinical efficacy according to the classification of bacterial pathogens 
 
Causative micro-organism 











Efficacy analysis set   535 479 37 19 92.8  
Undetected   333 288 30 15 90.6  
Bacterial pathogens  193 184 5 4 97.4  
Atypical pathogens  6 4 2 0 4/6 
Bacterial pathogens + atypical pathogens   3 3 0 0 3/3 
Efficacy rate = (Number of patients considered as “Effective”) / (Number of patients considered as 
“Effective” and “Ineffective”) 
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Table 8. Adverse drug reactions 
 
Category of adverse drug reactions 
 Incidence (%) 






(<65 years of age) 
Elderly 
(≥65 years of age) 
Number of patients with adverse drug reactions  58 (7.9) 31 (4.2) 27 (3.7) 
 Number of adverse drug reactions  71   38   33   
Infections and infestations  1 (0.1) 1 (0.1) 0 ( 0 ) 
Blood and lymphatic system disorders  3 (0.4) 1 (0.1) 2 (0.3) 
Nervous system disorders  2 (0.3) 1 (0.1) 1 (0.1) 
Cardiac disorders  1 (0.1) 0 ( 0 ) 1 (0.1) 
Respiratory, thoracic and mediastinal disorders  4 (0.5) 3 (0.4) 1 (0.1) 
Gastrointestinal disorders  8 (1.1) 3 (0.4) 5 (0.7) 
Hepatobiliary disorders  13 (1.8) 9 (1.2) 4 (0.5) 
Skin and subcutaneous tissue disorders  12 (1.6) 8 (1.1) 4 (0.5) 
Renal and urinary disorders  3 (0.4) 0 ( 0 ) 3 (0.4) 
General disorders and administration site conditions  3 (0.4) 1 (0.1) 2 (0.3) 
Investigations  15 (2.1) 6 (0.8) 9 (1.2) 
 Alanine aminotransferase increased  2 (0.3) 2 (0.3) 0 ( 0 ) 
 Aspartate aminotransferase increased  2 (0.3) 2 (0.3) 0 ( 0 ) 
 Blood creatine phosphokinase increased  1 (0.1) 1 (0.1) 0 ( 0 ) 
 Blood lactate dehydrogenase increased  1 (0.1) 1 (0.1) 0 ( 0 ) 
 Blood pressure decreased  1 (0.1) 0 ( 0 ) 1 (0.1) 
 Blood urea increased  2 (0.3) 0 ( 0 ) 2 (0.3) 
 Eosinophil count increased  1 (0.1) 0 ( 0 ) 1 (0.1) 
 Platelet count decreased  1 (0.1) 0 ( 0 ) 1 (0.1) 
 White blood cell count decreased  6 (0.8) 4 (0.5) 2 (0.3) 
 White blood cell count increased  1 (0.1) 0 ( 0 ) 1 (0.1) 
 Platelet count increased  1 (0.1) 0 ( 0 ) 1 (0.1) 
  Hepatic enzyme increased  1 (0.1) 0 ( 0 ) 1 (0.1) 
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This figure shows the number of patients for included or excluded each analysis set. 
Patients placed “a” include those with duplicated reasons for exclusion. 
Patients placed “b” exclude those who tested positive for S. pneumoniae in the urinary 
antigen test. 
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Figure 1. Analysis sets 
Survey form collected patients 739
Patients excluded from the safety analysis set a 9
Failure to follow-up 6
Not evaluated for safety 6
Violation of registration 3
Safety analysis set 730
Patients excluded from the efficacy analysis set a 195
Off-label use of GRNX (disease not indicated) 8
Contraindication 3
Did not meet the inclusion criteria 94
Only 1 day of GRNX therapy 3
Off-label use of GRNX (dosage not approved) 6
Not evaluated for efficacy 103
Efficacy analysis set 535
Patients not detected bacterial pathogens a 333
No bacteriological examination/rapid diagnosis/serological test 
before the initiation of GRNX therapy 29
Inadequate clinical specimens b 4
Off-label use of GRNX (bacteria not indicated) b 303
Bacterial pathogens detection set 202
Patients excluded from the bacteriological efficacy analysis set a 62
Identified bacterial pathogens by rapid diagnosis/serological test 
only 30
No bacteriological examination on the specified day after the 
initiation of GRNX therapy 45
Bacteriological efficacy analysis set 140
a Including patients with duplicated reasons for exclusion
b Excluding patients who tested positive for S. pneumoniae in the urinary antigen test
